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Purpose: To compare the efficacy and safety of repeat and initial trabeculectomy with mitomycine C (MMC).
Methods: Eighty seven patients, who had underwent repeat (repeat group) or initial (initial group) trabeculectomy 
with MMC, were enrolled in this prospective trial. Postoperative outcome measures included the amount of de-
crease in intraocular pressure (IOP), the number of anti-glaucoma medications, and the complications. The suc-
cess of trabeculectomy was defined on the basis of three definitions which were: IOP ≤18 mmHg (definition 1), 
IOP ≤21 mmHg (definition 2), and the amount of decrease in IOP from baseline ≥30% (definition 3). Success was 
further defined as “complete” when these criteria were obtained without any anti-glaucoma medications and 
“qualified” with or without medical therapy and no further surgical procedures. 
Results: Fifty nine eyes underwent initial and 28 eyes underwent repeat trabeculectomy. The mean follow-up period 
was 19.1 ± 5.9 months. Complete success rates were significantly greater in the initial trabeculectomy group (p = 
0.02 for definition 1, p = 0.038 for definition 2, p = 0.003 for definition 3). A higher proportion of eyes in the initial 
group achieved qualified success relative to the group A eyes, but the differences were not statistically significant 
(p = 0.33 for definition 1, p= 0.99 for definition 2, p = 0.24 for definition 3). The mean number of antiglaucomatous 
medications at the last examination was 1.2 ± 1.2 in repeat group and 0.7 ± 1.1 in initial group (p = 0.01). The 
number of complications during the follow up period did not differ significantly between the two groups (p = 0.65).
Conclusions: Repeat trabeculectomy with MMC has high success and low complication rates in patients with pre-
viously failed trabeculectomy in spite of the need of higher number of anti-glaucoma medications. 
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Trabeculectomy has become the golden standard for filter-
ing surgery of glaucoma since its introduction in 1967. The 
long-term successful control of intraocular pressure (IOP) in 
eyes that have undergone initial trabeculectomy varies from 
55% to 98%, depending on the follow-up period and the cri-
teria used to define success [1-5]. Despite initial success, there 
is a steady rate of failure in the subgroups of trabeculectomies. 
In most patients, the main reason of failure seems to be pro-
gressive fibrosis in the subconjunctival and episcleral tissues 
[1,6,7]. 
The Fluorouracil Filtering Surgery Group [8] considers 
previous unsuccessful filtering surgery as a high risk factor 
for poor prognosis of trabeculectomy. The risk is attributed to 
the previous surgery involving conjunctiva itself. Broadway 
et al. [9] found that the previous conjunctival surgery induced 
the general increase in subepithelial conjunctival fibroblasts. 
Zalish et al. [10] suggest that the outcome of trabeculectomy is 
highly influenced by the patients wound healing characteristics. 
Therefore eyes undergoing repeat surgery can be accepted 
“at risk” because they have already failed at least once. In pa-
tients at high risk for failure, intraoperative application of mi-
tomycin C (MMC) has been found to be as an effective anti-
fibrotic agent in increasing surgical success [11].   
Failure of filtration surgery may be managed in a number 
of ways. In the early postoperative period, digital massage, 
scleral flap suture lysis, releasable-suture removal can be 
attempted. Medical therapy is often reinstituted which prob-
ably lead to increased fibrosis and the eventual closure of the 
guarded filter [12,13]. A significant proportion of these pa-Korean J Ophthalmol Vol.25, No.6, 2011
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Table 1. Baseline demographic data and clinical characteristics of study population 
      Repeat group       Initial group p-value
Age (yr) 63.4 ± 5.9 (54-75) 65.8 ± 6.8 (45-78) 0.12
Gender (male / female  ratio)   18 / 10 36 / 23 0.82
POAG / EXG  19 / 9 36 / 23 0.64
Duration glaucoma (yr) 8.2 ± 3.1 (4-16) 5.7 ± 2.9 (0.5-13)    0.001
*
Diabetes mellitus (+ / -) 11 / 17 21 / 38 0.81
IOP (mmHg) 25.9 ± 3.9 (20-35) 25.3 ± 3.7 (19-35) 0.48
Pachymetry  (μm)    542.4 ± 37.7 (475-605) 536.7 ± 28.4 (485-605) 0.43
No. of medications 2.9 ± 0.8 (2-4) 2.9 ± 0.7 (2-4) 0.92
Cup/disc ratio    0.8 ± 0.1 (0.5-1.0)   0.8 ± 0.1 (0.5-1.0) 0.23
Visual acuity (n)     ≤0.1 5  6
                             0.2-0.5 6 10 0.47
                             ≥0.6 17 43
t-test and the chi-square test used for comparisons of the continous and categorical data respectively.
POAG = primary open angle glaucoma; EXG = exfoliative glaucoma; IOP = intraocular pressure.
*Statistically significant.
tients are refractory to medical treatment and further surgery 
is the only option. The surgical alternatives include subcon-
junctival needle revision [14], reopening of the scleral flap 
and excision of fibrotic subconjunctival tissues [15], repeat 
trabeculectomy [16,17], and glaucoma drainage devices. 
The use of anti-fibrotic agents are generally accepted as 
improving the outcome of primary trabeculectomy with re-
ported success rates from 73% to 93% [18-20]. The aim of 
this study was to study the comparative outcomes of MMC- 
enhanced initial and repeat trabeculectomy.
Materials and Methods
In this prospective study, 87 eyes of 87 consecutive pri-
mary open angle glaucoma and exfoliative glaucoma patients 
who underwent trabeculectomy augmented with MMC from 
June 2006 to June 2008 were analyzed. All patients had un-
controlled IOP greater than 18 mmHg despite maximally tol-
erated medications. Twenty eight patients had undergone one 
previous failed trabeculectomy and underwent repeat trabe-
culectomy (repeat group) and 59 of patients underwent initial 
trabeculectomy (initial group). Bleb failures in repeat group 
were considered as late failures (occur after the first post-
operative month which are usually a result of subconjunctival/ 
episcleral fibrosis). Ethics committee approval was obtained 
for the study. The procedures followed were in accordance 
with the Helsinki Declaration of 1975. All the patients signed 
informed consent forms.
Eyes with a history of conjunctival or intraocular surgery 
other than trabeculectomy and patients with a follow-up peri-
od of less than 12 months or who had any significant ocular 
disease other than glaucoma were not included in this study 
(7 patients from repeat group and 18 patients from initial 
group had been excluded before 12 months due to missed the 
scheduled follow-up examination or noncompliance with 
postoperative anti-inflamatuar therapy). It was prospectively 
decided that if both eyes of a patient undergo trabeculectomy, 
the eye that was operated first would be included in the 
analysis. 
Complete ocular examination was performed in all patients 
including best-corrected visual acuity with Snellen charts, 
preoperative IOP with Goldmann applanation tonometry, 
fundoscopy (cup/disk ratio assessment) with 90 diopter lens, 
gonioscopy with Goldmann three-mirror lens, visual-field 
analysis with Humphrey automated perimeter, central corneal 
thickness measurement with ultrasonic pachymeter. The di-
agnosis of glaucoma was based on elevated IOP (>21 
mmHg), glaucomatous optic disc cupping (cup/disk ratio ≥
0.5), the presence of an abnormal Glaucoma Hemifield Test, 
mean deviation and pattern standard deviation outside nor-
mal limits and characteristic glaucomatous visual field de-
fects (nasal step, arcuate scotoma etc). Recorded variables 
included patient age, sex, type of glaucoma, number of an-
ti-glaucoma medications and their durations of use, and the 
period between the initial and repeat trabeculectomy with 
MMC (for repeat group) (Table 1). 
The indication for trabeculectomy was considered on the 
basis of insufficient IOP control and/or the progression of 
visual field damage in spite of maximal tolerated anti-glaucoma 
medications. All patients underwent standard trabeculectomy 
procedure which were performed by two surgeons (ABC and 
UE).
Surgical technique 
After administration of regional anesthesia, a fornix-based 
conjunctival flap was created at one of the the superior 
quadrants. For patients with failed filtering surgery, con-
junctival flap site was choosen to avoid the previous surgical 
site. A 4 × 4 mm triangular, one-half scleral thickness scleral 
flap was dissected, extending into the clear cornea. All sur-
geries were augmented with intraoperative subconjunctival AB Cankaya, et al. Repeat Trabeculectomy with Adjunctive Mitomycin C
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Table 2. Postoperative mean IOP values over time 
Repeat group Initial group  p-value
IOP    postop 1st day (mmHg)   8.8 ± 3.3 (5-18)   9.8 ± 4.1 (4-24) 0.22
          postop 1st wk 14.1 ± 4.6 (8-26) 12.8 ± 4.2 (6-22) 0.21
          postop 1st mon 16.4 ± 4.1 (9-24) 14.3 ± 3.4 (9-23) 0.01
*
          postop 3rd mon 17.4 ± 3.4 (8-24) 14.8 ± 4.2 (9-24) 0.008
*
          postop 6th mon 17.1 ± 3.3 (11-24) 15.6 ± 4.6 (9-27) 0.12
          postop 9th mon 18.2 ± 3.4 (12-26) 17.4 ± 4.0 (8-26) 0.33
          postop 12th mon 18.3 ± 3.0 (14-25) 17.4 ± 3.9 (10-25) 0.29
          postop 18th mon 17.7 ± 2.6 (13-22) 17.6 ± 4.6 (10-27) 0.96
          postop 24th mon 17.1 ± 3.0 (13-23) 16.4 ± 3.4 (8-21) 0.59
          Final visit 18.1 ± 3.1 (13-25) 17.3 ± 4.1 (8-27) 0.41
Mean follow-up duration (mon) 19.4 ± 5.6 (12-30) 18.8 ± 6.1 (12-36) 0.58
Reduction in IOP (%) (final visit) 28.7 ± 16.3 (-51.8-+5.0) 31.21 ± 15.8 (-73.3-+5.5) 0.49
Patients with medication (final visit)   17 (60.7%)   20 (33.9%) 0.02
*
Medication (final visit)   1.2 ± 1.2 (0-4)  0.7 ± 1.1 (0-4) 0.04
*
t-test used to calculate significance.
IOP = intraocular pressure; postop = postoperative.
*Statistically significant. 
0.02% MMC application for 2 minutes with a wide applica-
tion area. Following removal of the sponge, the site was irri-
gated copiously with balanced saline solution. After trabecu-
lectomy, peripheral iridectomy was performed. The flap was 
closed with one to three 10-0 nylon sutures. Conjunctiva was 
reapproximated with 8-0 Vicryl sutures. Steroid and anti-
biotic injections were routinely administered at the end of the 
surgery. 
Postoperatively, topical cyclopentholate 1% t.i.d., pre-
dnisolone acetate 1% q.i.d., and netilmycin 0.3% q.i.d. were 
given for at least 2 months. Anti-glaucomatous medications 
were discontinued immediately after surgery and then ad-
justed according to postoperative IOP. The surgical technique 
and postoperative care did not vary based on how many times 
trabeculectomy was performed. Intra- and postoperative 
complications and any additional surgery (resuturation, refor-
mation of the anterior chamber, etc.) were recorded.
Following trabeculectomy, patients were examined at the 
first and the seventh postoperative days, at the 1st, 3rd, 6th, 
9th, 12th, and 24th months, or more often if necessary. Visual 
acuity, biomicroscopic examination, IOP, postoperative 
complications, and the number of anti-glaucoma medications 
prescribed were recorded at each follow-up visit. Data avail-
able from the most recent clinic visit were used in the final 
determination of surgical outcome(i.e., the last IOP measure-
ment was taken for the analysis) to maximize the duration of 
follow-up.
Outcome of filtration surgery was assessed on the criteria 
of IOP control. Three success criteria were defined; defi-
nition 1: IOP ≤18 mmHg, definition 2: IOP ≤21 mmHg, defi-
nition 3: more than 30% decrease in preoperative IOP. The 
success was further defined as “complete” if the IOP was ≤18 
mmHg, ≤21 mmHg or a ≥30% decrease was present in the 
preoperative IOP without anti-glaucoma medications. The 
criteria for “qualified success” was maintaining the defined 
IOP levels with or without medications. Ocular hypotony 
was considered to be present if the IOP was less than 5 
mmHg. The anterior chamber was judged as shallow or flat 
when the peripheral angle width was ≤1/4 of the peripheral 
corneal thickness. 
To maintain IOP control, topical glaucoma therapies 
and/or 5-FU injections were carried out when necessary. The 
date when glaucoma medication had been restarted was 
noted. The failure was defined as uncontrolled IOP despite 
medical treatment or when an additional intervention 
(needling, bleb revision, repeat surgery) was required. If fail-
ure occurred, the exact time of it was recorded.
Statistical analysis was performed using t-tests for com-
parison of the continous variables as IOP and the number of 
anti-glaucoma medications. Categorical data, were analyzed 
using the Fisher’s exact or Pearson χ
2 tests. The probability 
of continued success with time after surgery was estimated 
using Kaplan-Meier analysis and survival curves were drawn 
for the two groups of patients. Survival was defined on the 
basis of three definitions of successful IOP control. The sig-
nificance level of the difference between the two groups in 
the Kaplan-Meier survival curves was calculated with the 
log-rank test. A p-value of ≤0.05 was considered significant. 
Results
Fifty four male (62.1%) and 33 female (37.9%) patients 
were included in our study. The mean age of the patients was 
65.0 ± 6.6 years (range, 45 to 78 years), and the mean period 
from the diagnosis of glaucoma was 6.5 ± 3.2 years (range, 
0.5 to 16 years). Patients were under the mean 2.9 ± 0.7 
(range, 2 to 4) anti-glaucoma medications and the mean IOP 
just before surgery was 25.5 ± 3.8 mmHg (range, 19 to 35 Korean J Ophthalmol Vol.25, No.6, 2011
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Table 3. Bleb morphology after index trabeculectomy
Repeat group Initial group p-value
Diffuse-elevated 13 (46.4) 30 (50.8) 0.82
Cystic 1 (3.6) 6 (10.2) NC
Encapsulated   3 (10.7) 8 (13.6) NC
Flat 11 (39.3) 15 (25.4) 0.8
Values are presented as number (%).
NC = not computed (because one cell have count less than the minimum expected count).
Table 4. Number and percentage of patients achieving successful outcomes for surgery at final follow-up for various 
definitions of intraocular pressure
      Group
Success 1 (IOP ≤18 mmHg) Success 2 (IOP ≤21 mmHg) Success 3 (IOP ≤30%)
Complete Qualified  Complete  Qualified  Complete  Qualified 
Repeat     N   8 16 11 23   6 14
              % 28.6 57.1 39.3 82.1 21.4 50.0
Initial       N      35 41 38 49 33 38
               % 59.3 69.5 64.4 83.1 55.9 64.4
p-value  0.007
*  0.186  0.024
*  0.569  0.002
*   0.148
IOP = intraocular pressure.
*Statistically significant.
mmHg). The mean postoperative follow-up period was 19.1 
± 5.9 months (range, 12 to 36 months). Sixty three eyes had at 
least 18 months and 29 eyes had at least 2 years of follow-up 
period.
Information regarding baseline characteristics for groups 
A and B are listed in Table 1. There were no statistically sig-
nificant differences between the two groups in regard to these 
baseline characteristics except the preoperative duration of 
glaucoma. The mean duration of glaucoma was longer in re-
peat group (8.2 ± 3.1 years; range, 4.0 to 16.0 years) than ini-
tial group (5.7±2.9 years; range, 0.5 to 13 years) (p = 0.001). 
In repeat group the period between the initial and repeat tra-
beculectomies varied from 12 months to 10 years (mean, 
28.6 ± 24.6 months). Nine patients in repeat group had un-
dergone failed glaucoma surgery augmented with MMC 
and remaining 19 patients had failed surgery without MMC 
application.
In the study group, the mean postoperative IOP at the final 
visit was 17.5 ± 3.8 mmHg (range, 8 to 27 mmHg) and the 
mean percentage of reduction in IOP from the preoperative 
levels was 30.4 ± 15.9% (range from 5.5% increase to 73.3% 
decrease). The difference between mean baseline and final 
postoperative IOP was statistically significant (p < 0.001). 
IOP had risen above preoperative levels in 3 eyes (10.7%) in 
repeat group and 5 eyes (8.5%) in initial group. The average 
of number of anti-glaucoma medications was decreased to 
0.9 ± 1.2 (range, 0 to 4) at final visit. The mean reduction in 
the number of anti-glaucoma medications was also sig-
nificant (p < 0.001). Anti-glaucoma medications were started 
7.3 ± 4.3 months (3 to 18 months) after surgery for repeat 
group and 6.5 ± 4.1 months (1 to 16 months) for initial group 
(p = 0.27).
Table 2 compares the differences in postoperative IOP, 
percentage of reduction in IOP and postoperative medi-
cations between the two groups at their visits. Mean final 
postoperative IOP measurements were 18.1 ± 3.1 mmHg (13 
to 25 mmHg) and 17.3 ± 4.1 mmHg (8 to 27 mmHg) in the re-
peat and initial trabeculectomy groups, respectively (p = 
0.41). However, it was notable that; at the last examination, 
60.7% of eyes in repeat group but only 33.9% of eyes in ini-
tial group were with IOP-lowering medications (p = 0.02). 
The distribution of blebs according to morphology is 
shown in Table 3. No difference was found in the frequency 
of functional (either cystic or diffuse) and non functional 
bleb (either encapsulated or flattened) morphology in the two 
groups. 
Table 4 shows the number and percentage of eyes which 
obtained success in groups A and B defined by various arbi-
trary IOP criteria. Regardless of the definition, complete suc-
cess was significantly more common in initial group eyes 
than in repeat group eyes (p = 0.014 for definition 1, p = 
0.042 for definition 2, p = 0.004 for definition 3). The great-
est difference between repeat group and initial group was 
seen when complete success was defined as more than 30% 
decrease in IOP (21.4% vs. 55.9%, respectively). Also like 
complete success, lower proportion of eyes in repeat group 
achieved qualified success than initial group regardless of the 
criterion for success. However these differences were not 
statistically significant (p = 0.335 for definition 1, p = 0.245 
for definition 3). The likelihood of achieving an IOP less than 
21 mmHg ± medications (i.e., definition 2) was almost sim-
iliar for both groups (p = 0.99).    
Types of surgical interventions that had been carried out is 
shown in Table 5. The mean intervention period after the sur-AB Cankaya, et al. Repeat Trabeculectomy with Adjunctive Mitomycin C
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Table 5. Subsequent surgical procedures after index trabeculectomy
Repeat group Initial group p-value
5 Fluorouracil injection  11 (39.3) 10 (16.9) 0.21
Needling 2  (7.1) 0 NC
Repeat trabeculectomy  0 5 (8.5) NC
Revision of bleb  2 (7.1) 2 (3.4) NC
Anterior chamber reformation  1 (3.6) 3 (5.1) NC
Total 16 (57.1) 20 (34) 0.002
*
Values are presented as number (%).
NC = not computed (because one cell have count less than the minimum expected count).
*Statistically significant.
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Fig. 1. Kaplan-Meier survival analysis of complete success rates of 
intraocular pressure control. (A) Definition 1, (B) definition 2, (C) 
definition 3. trab = trabeculectomy.
gery was 1.2 ± 2.0 months (0 to 9 months) in repeat group and 
2.5 ± 6.0 months (0 to 20 months) in initial group (p = 0.27). 
There was no re-operation like repeat trabeculectomy or 
glaucoma drainage device impantation in repeat group cases. 
Repeat trabeculectomy had been carried out in 5 eyes of the 
initial group. The data from these re-operations were not ana-
lyzed as repeat group data. 
Using Kaplan-Meier survival analysis and comparing the 
repeat and initial groups survival curves with a log-rank test, 
we found that the patients who underwent initial trabeculec-
tomy had a greater probability of survival than patients who 
had undergone previous surgery. But these differences were 
not statistically significant (p = 0.11 for definition 1, p = 0.14 
for definition 2, p = 0.06 for definition 3). According to 
Kaplan-Meier survival analysis the probability of maintain-
ing an IOP ≤18 mmHg, ≤21 mmHg and 30% decrease from 
preoperative IOP in repeat group were 25.5%, 32.6%, 
17.0%; and in initial group were 47.7%, 52.1%, 45.7% re-
spectively without medications 2 years after surgery (Fig. 1). 
Estimation of qualified success for definitions 1, 2, 3 showed 
that 55.8%, 84.4%,and 55.2% of patients in repeat group at 2 
years, respectively, versus 60.8%, 73.2% and 54.5% of initial 
group patients (Fig. 2). Survival curves were compared using 
the log-rank test and showed no statistically significant dif-
ference (p = 0.46, p = 0.92, p = 0.35, respectively).  
The early complications observed during the first post-
operative month included a shallow or flat anterior chamber 
in 24 (27.6%) of 87 eyes, hyphema in 8 eyes (9.2%), mild 
choroidal detachment (confined to anterior to equator) in 11 
eyes (12.6%), and early wound leak in 26 eyes (29.9%). 
Table 6 compares the number and percentage of early post-
operative adverse outcomes between initial and repeat sur-
gery groups. None of the eyes either group, developed hypot-
ony maculopathy or endophhalmitis. The number of compli-
cations during the follow up period did not differ sig-
nificantly between the two groups (p = 0.65). Eight eyes in 
repeat group and 10 eyes in initial group developed more 
than one complications. One eye in repeat group, and 3 eyes 
in initial group, had lost two or more lines of Snellen acuity at 
the last follow up visit compared with their preoperative 
acuity. In all eyes, it was attributed to cataract progression. 
For both groups differences between the preoperative and 
postoperative visual acuity on the Snellen chart were not stat-
istically significant (p = 0.79). Korean J Ophthalmol Vol.25, No.6, 2011
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Fig. 2. Kaplan-Meier survival analysis of qualified success rates of 
intraocular pressure  control. (A) Definition 1, (B) definition 2, (C) 
definition 3. trab = trabeculectomy.
Table 6. Early postoperative complications of trabeculectomy encountered in the present study 
Repeat group Initial group p-value
Shallow AC   9 (32.1) 15 (25.4) 0.32
Fibrin in AC   3 (10.7) 3 (5.1) 0.38
Hyphema    2 (7.1)  6 (10.2) NC
Conjunctival flap edge-leaks   5 (17.9)  6 (10.2) 0.32
Conjunctival flap retraction 0 1 (1.7) NC
Choroidal detachments    4 (14.3)   7 (11.9) 0.72
Total 23 (82.1) 38 (64.5) 0.65
Values are presented as number (%).
AC = anterior chamber; NC = not computed (because one cell have count less than the minimum expected count). 
Discussion
The present long-term prospective analysis shows that, the 
difference between the outcomes of the initial and repeat tra-
beculectomy is minimal in regard to “qualified success”. On 
the other hand, regardless of the definition, complete success 
was significantly more common in the initial group and 
greater proportion of eyes in the repeat group needed post-
operative anti-glaucoma medications. Postoperative compli-
cation rates were similar in the eyes of two groups.
It has been proposed that previous intraocular surgery is 
associated with the breakdown of the blood-aqueous barrier, 
alterations to the composition of growth factors in aqueous 
and a subsequent greater wound-healing response [21,22]. 
Moreover, the effect of previous conjunctival surgery other 
than intraocular one has been shown as a significant risk fac-
tor for failure of filtration surgery [9]. It has been shown that 
the conjunctival changes induced by a previous surgery in-
cludes the general increase in subepithelial conjunctival cel-
lularity especially an increase in the number [8]. It can also 
be suggested that preexisting conjunctival fibrosis may pro-
mote further scarring. Moreover conjunctival scarring at the 
surgical site may cause technical difficulties on subsequent 
trabeculectomy.   
In clinical practice, bleb failure tends to occur early and 
usually caused by the production, contraction, and remodel-
ing of collagen leading to excessive scarring at the con-
junctival episcleral interface. As is well known, the use of in-
traoperative and postoperative antimetabolites for the manip-
ulation of wound healing and to reducion of the postoperative 
subconjunctival scarring response improve the outcome of 
trabeculectomy [20,23-25]. Reported surgical success rates 
differ from 78% to 84% in high-risk eyes with the use of ad-
juvant MMC [26,27]. 
The question of which management strategy is desirable in 
eyes with failed initial trabeculectomy has long been debated. 
Postoperative bleb manipulation such as massage, laser su-
turelysis, removing of releasable sutures, alteration of the 
tension via adjustable sutures and needling are now consid-
ered important parts of postoperative trabeculectomy bleb 
management [28]. 
Needling is one of the management strategies in eyes with 
a failing bleb. Broadway et al. [29] demonstrated that, nee-
dlings augmented with 5-FU in the postoperative period, had 
a mean success rate of nearly 60%. Gutierrez-Ortiz et al. [30] AB Cankaya, et al. Repeat Trabeculectomy with Adjunctive Mitomycin C
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found that the outcome of needling with MMC, was better 
within 4 months after trabeculectomy. The major limitation 
of needling procedure is the invisible outline of the flap 
found in most of the eyes with failed blebs due to excessive 
scar tissue.
Success rate of surgical reopening of the failed blebs after 
filtration procedure with antimetabolite augmentation has 
been reported (maintaining an IOP less 18 mmHg with medi-
cations) as 64% [15]. Difficulty of watertight closure and a 
high incidence of early complications were the major com-
plexity of reopening the failed filter. Another possible dis-
advantage of reopening the failed trabeculectomy blebs is the 
difficulty in dissection that may be hampered by bleeding.
Altough, there have been no previous reports which pro-
spectively compares the outcomes of initial and repeat trabe-
culectomies, glaucoma surgery in an eye with failed initial 
trabeculectomy is often postponed because of the risk of pos-
sible failure and medical therapy is generally preferred. 
Additionally, repeat surgical treatment is accepted as a tech-
nically more difficult procedure. In our study, we had no sur-
gical difficulty in repeat trabeculectomy procedures espe-
cially if the first operation had been performed on nasal or 
temporal superior quadrants. Moreover, there was no statisti-
cally significant difference in the number of eyes with com-
plications between the initial and repeat trabeculectomy 
groups. 
Recently Law et al. [31] evaluated retrospectively the out-
comes and risk factors of repeat trabeculectomy with MMC 
as compared with that of initial trabeculectomy with MMC. 
Investigators reported significantly higher rates of failure for 
repeat trabeculectomy with more stringent success criteria. 
With looser IOP reduction criteria the difference between the 
2 groups was not found statistically significant. In accord-
ance with the present study, eyes that underwent repeat trabe-
culectomy required a higher average number of medications 
than those that underwent initial trabeculectomy.
You et al. [16] reported the results repeat trabeculectomies 
augmented with subconjunctival or both subconjunctival and 
subscleral flap application of MMC in eyes with failed initial 
filtering operation. The total success rates were 86.4%, 
90.9%, respectively. Broadway et al. [9] on the other hand, 
investigated the outcome of repeat trabeculectomy without 
antimetabolites and found that the surgical success in the 
re-operated eye was 38%. Their study group consisted of pa-
tients with developmental or secondary glaucoma. The use of 
anti-metabolites in all of our patients are probably respon-
sible for the higher success rate in our study. Cohen et al. [17] 
in a retrospective study on repeat trabeculectomy with sub-
conjunctival MMC, reported that history of previous surgery 
did not correlate with postoperative IOP and medications.
One of the major limitations of our study was the modest 
sample size and follow-up time which may affect the validity 
of our conclusions and their significance. The durations of 
glaucoma were significantly different in both groups produc-
ing the bias of glaucoma severity on the outcome of 
trabeculectomy. On the other hand; it is certain that, a longer 
duration of disease is to be expected if an eye is undergoing a 
repeat operation. Another limitation of the study is that the 
criteria for using IOP-lowering medications after trabeculec-
tomy was not standardized.
In conclusion, repeat trabeculectomy augmented with 
MMC seems to be effective in IOP control. In spite of the 
need of higher number of anti-glaucoma medications success 
rates in repeat trabeculectomies with the use of MMC could 
be comparable with the results of patients who underwent in-
itial trabeculectomy without significant increase in the rate of 
complications. This information may be useful for planning 
the surgery in eye with failed bleb and enables the surgeon to 
counsel the patient before surgery. Results of this study also 
provide a rationale for the use of antifibrotic agents when 
performing repeat trabeculectomy.
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